NASDAQ:PSTV Plus Therapeutics (PSTV) Stock Price, News & Analysis $1.90 +0.10 (+5.56%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$1.75▼$1.9650-Day Range$1.46▼$2.6052-Week Range$0.97▼$3.21Volume98,825 shsAverage Volume56,724 shsMarket Capitalization$10.83 millionP/E RatioN/ADividend YieldN/APrice Target$8.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestTrends Get Plus Therapeutics alerts: Email Address Plus Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside321.1% Upside$8.00 Price TargetShort InterestHealthy3.80% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.62Based on 3 Articles This WeekInsider TradingAcquiring Shares$55,000 Bought Last QuarterProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.71 out of 5 starsMedical Sector472nd out of 936 stocksSurgical & Medical Instruments Industry63rd out of 101 stocks 3.5 Analyst's Opinion Consensus RatingPlus Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoveragePlus Therapeutics has received no research coverage in the past 90 days.Read more about Plus Therapeutics' stock forecast and price target. Previous Next 5.0 Short Interest Percentage of Shares Shorted3.80% of the float of Plus Therapeutics has been sold short.Short Interest Ratio / Days to CoverPlus Therapeutics has a short interest ratio ("days to cover") of 2.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Plus Therapeutics has recently decreased by 9.18%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldPlus Therapeutics does not currently pay a dividend.Dividend GrowthPlus Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for PSTV. Previous Next 2.6 News and Social Media Coverage News SentimentPlus Therapeutics has a news sentiment score of 0.62. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Plus Therapeutics this week, compared to 1 article on an average week.Search Interest1 people have searched for PSTV on MarketBeat in the last 30 days. MarketBeat FollowsOnly 1 people have added Plus Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Plus Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $55,000.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 2.32% of the stock of Plus Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 3.28% of the stock of Plus Therapeutics is held by institutions.Read more about Plus Therapeutics' insider trading history. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Plus Therapeutics is -0.63, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Plus Therapeutics is -0.63, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Plus Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad DarwinTop Stock Unveiled!Ready to discover the standout stock of 2024? We’ve identified a single buy & hold gem that’s poised to redefine your portfolio. Download our exclusive report now and dive into the Insights. Click below to opt-in and receive up to two additional free bonus subscriptions. Unsubscribe at any time.Get Your Free Report About Plus Therapeutics Stock (NASDAQ:PSTV)Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. Its lead radiotherapeutic drug candidate is rhenium (186Re) obisbemeda, a patented radiotherapy that targets central nervous system cancers and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. The company also develops Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere that is designed to treat various solid organ cancers comprising primary and secondary liver cancers by intra-arterial injection. It has license agreements with NanoTx, Corp. and The University of Texas Health Science Center at San Antonio. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas.Read More PSTV Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PSTV Stock News HeadlinesJuly 25 at 9:05 AM | markets.businessinsider.comPlus Therapeutics Showcases Leptomeningeal Metastases Programs at 2024 SNO/ASCO ConferenceJuly 25 at 7:30 AM | globenewswire.comPlus Therapeutics Showcases Leptomeningeal Metastases Programs at 2024 SNO/ASCO ConferenceJuly 26, 2024 | Crypto Swap Profits (Ad)625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.July 2, 2024 | globenewswire.comPlus Therapeutics to Present at the Gordon Research Conference Radionuclide Theranostics for the Management of CancerJune 7, 2024 | globenewswire.comPlus Therapeutics Expands Management Team and Reports $3.3M Advance Payment from CPRITMay 18, 2024 | finanznachrichten.dePlus Therapeutics Inc.: Plus Therapeutics Announces New Employment Inducement GrantsMay 17, 2024 | globenewswire.comPlus Therapeutics Announces New Employment Inducement GrantsMay 16, 2024 | msn.comPlus Therapeutics, Inc. (NASDAQ:PSTV) Q1 2024 Earnings Call TranscriptJuly 26, 2024 | Crypto Swap Profits (Ad)625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.May 16, 2024 | finance.yahoo.comPlus Therapeutics Inc (PSTV) Q1 2024 Earnings Call Transcript Highlights: Strategic Progress ...May 15, 2024 | sfgate.comPlus: Q1 Earnings SnapshotMay 15, 2024 | markets.businessinsider.comPlus Therapeutics Inc. Q1 Loss Decreases, Beats EstimatesMay 15, 2024 | globenewswire.comPlus Therapeutics Reports First Quarter 2024 Financial Results and Recent Business HighlightsMay 13, 2024 | globenewswire.comPlus Therapeutics to Announce First Quarter Financial Results and Host Conference Call on May 15, 2024May 12, 2024 | uk.investing.comPlus Therapeutics CEO buys $25,000 in company stockMay 10, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Charles River Labs (CRL), Plus Therapeutics (PSTV) and Argenx Se (ARGX)May 9, 2024 | globenewswire.comPlus Therapeutics Provides Highlights Regarding Leptomeningeal Metastases Acquisition and Topline Clinical Trial Data on the FORESEE TrialMay 8, 2024 | globenewswire.comPlus Therapeutics to Host Investor Call to Discuss Leptomeningeal Cancer Related Acquisition and Topline Clinical Trial Data from the FORESEE TrialSee More Headlines Receive PSTV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Plus Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/15/2024Today7/26/2024Next Earnings (Estimated)8/12/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryN/A Current SymbolNASDAQ:PSTV CUSIPN/A CIK1095981 Webwww.plustherapeutics.com Phone737-255-7194Fax858-450-4335Employees20Year Founded1996Price Target and Rating Average Stock Price Target$8.00 High Stock Price Target$8.00 Low Stock Price Target$8.00 Potential Upside/Downside+342.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($3.04) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-13,320,000.00 Net Margins-193.49% Pretax Margin-193.49% Return on Equity-805.57% Return on Assets-105.85% Debt Debt-to-Equity RatioN/A Current Ratio0.41 Quick Ratio0.41 Sales & Book Value Annual Sales$4.91 million Price / Sales2.10 Cash FlowN/A Price / Cash FlowN/A Book Value($0.30) per share Price / Book-6.03Miscellaneous Outstanding Shares5,700,000Free Float5,572,000Market Cap$10.32 million OptionableNot Optionable Beta0.54 Social Links 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleGrowth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.Get This Free Report Key ExecutivesDr. Marc H. Hedrick M.B.A. (Age 61)M.D., President, CEO & Director Comp: $945.34kMr. Andrew J. Sims CPA (Age 51)VP of Finance & CFO Comp: $498.51kDr. Norman D. LaFrance FACNP (Age 76)FACP, M.D., Chief Medical Officer & Senior VP Comp: $646.02kMs. Desiree Smith (Age 60)Corporate Controller, Principal Financial & Accounting Officer Dr. John K. Fraser (Age 63)Chief Scientist Key CompetitorsIceCure MedicalNASDAQ:ICCMDarioHealthNASDAQ:DRIOiCADNASDAQ:ICADAkiliNASDAQ:AKLIRetractable TechnologiesNYSE:RVPView All CompetitorsInsidersHoward ClowesBought 9,804 shares on 5/8/2024Total: $20,000.16 ($2.04/share)Marc H HedrickBought 12,255 shares on 5/8/2024Total: $25,000.20 ($2.04/share)Andrew John Hugh Macintyr SimsBought 4,902 shares on 5/8/2024Total: $10,000.08 ($2.04/share)Marc H HedrickSold 2,068 sharesTotal: $4,053.28 ($1.96/share)Robert P LenkBought 1,000 shares on 11/15/2023Total: $1,770.00 ($1.77/share)View All Insider Transactions PSTV Stock Analysis - Frequently Asked Questions How have PSTV shares performed this year? Plus Therapeutics' stock was trading at $1.7501 on January 1st, 2024. Since then, PSTV stock has increased by 8.6% and is now trading at $1.90. View the best growth stocks for 2024 here. How were Plus Therapeutics' earnings last quarter? Plus Therapeutics, Inc. (NASDAQ:PSTV) released its quarterly earnings results on Wednesday, May, 15th. The company reported ($0.75) earnings per share for the quarter, topping analysts' consensus estimates of ($1.09) by $0.34. The company had revenue of $1.68 million for the quarter. Plus Therapeutics had a negative trailing twelve-month return on equity of 805.57% and a negative net margin of 193.49%. When did Plus Therapeutics' stock split? Plus Therapeutics shares reverse split on the morning of Monday, May 1st 2023. The 1-15 reverse split was announced on Monday, May 1st 2023. The number of shares owned by shareholders was adjusted after the market closes on Monday, May 1st 2023. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. How do I buy shares of Plus Therapeutics? Shares of PSTV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Plus Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Plus Therapeutics investors own include Advanced Micro Devices (AMD), Trevena (TRVN), Chimerix (CMRX), Genocea Biosciences (GNCA), Sorrento Therapeutics (SRNE) and Akero Therapeutics (AKRO). This page (NASDAQ:PSTV) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredCollapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | Sponsored5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Plus Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Plus Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
